Alkermes Q2 2024 Earnings Report $34.59 -0.20 (-0.58%) As of 03:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Alkermes EPS ResultsActual EPS$0.70Consensus EPS $0.70Beat/MissMet ExpectationsOne Year Ago EPS$0.38Alkermes Revenue ResultsActual Revenue$399.13 millionExpected Revenue$393.30 millionBeat/MissBeat by +$5.83 millionYoY Revenue Growth-35.40%Alkermes Announcement DetailsQuarterQ2 2024Date7/24/2024TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptSlide DeckPress ReleaseALKS Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Slide DeckFull Screen Slide DeckPowered by Alkermes Earnings HeadlinesAlkermes plc (NASDAQ:ALKS) Receives $38.36 Consensus Target Price from AnalystsFebruary 27 at 2:36 AM | americanbankingnews.comAlkermes to Participate in Upcoming Investor ConferencesFebruary 26 at 4:00 PM | prnewswire.comFBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…February 27, 2025 | Colonial Metals (Ad)Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy TreatmentFebruary 25 at 6:00 AM | seekingalpha.comAlkermes (ALKS) Projected to Post Earnings on ThursdayFebruary 18, 2025 | americanbankingnews.comHC Wainwright Predicts Alkermes' Q1 Earnings (NASDAQ:ALKS)February 18, 2025 | americanbankingnews.comSee More Alkermes Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alkermes? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alkermes and other key companies, straight to your email. Email Address About AlkermesAlkermes (NASDAQ:ALKS), a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.View Alkermes ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings? Upcoming Earnings CrowdStrike (3/4/2025)Arista Networks (3/4/2025)AutoZone (3/4/2025)Target (3/4/2025)Marvell Technology (3/5/2025)Broadcom (3/6/2025)Costco Wholesale (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
